Oryzon Genomics S.A. (Oryzon) is a biopharmaceutical company. The company develops therapies and biological solutions for cancer and neurodegenerative diseases. It concentrates on the exploitation of biomarkers identified through genomics and proteomics in diagnostics, personalized medicine and therapy fields. Oryzons diagnostic products include GynEC-DX for endometrial cancer; Cxbladder for bladder cancer; and ColoBRAF for colorectal cancer. The company produces NCEs and monoclonal antibodies for neurogeneration and cancer. It collaborates with Eurostarts, Mind, Dendria, Oncologica, Alzheimer Drug Discovery Foundation, among others. Oryzon is headquartered in Barcelona, Spain.
This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.
We can provide sample pages for the better understanding of this report. Request Sample of This Report, kindly Visit at http://www.marketresearchreports.biz/sample/sample/223510
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Oryzon Genomics S.A.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical...